You are here

  • Home
  • Archive
  • Volume 80, Issue 10
  • Response to: ‘Correspondence on ‘Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries’ by Nokhatha et al

Article Text

Article menu
Download PDFPDF
Correspondence response
Response to: ‘Correspondence on ‘Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries’ by Nokhatha et al
  1. Christian Dejaco1,2,
  2. Johannes WJ Bijlsma3,
  3. Frank Buttgereit4
  1. 1 Rheumatology, Medical University of Graz, Graz, Austria
  2. 2 Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy
  3. 3 Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
  4. 4 Rheumatology and Immunology, Charitè University, Berlin, Germany
  1. Correspondence to Dr Christian Dejaco, Rheumatology, Medical University of Graz, 8036 Graz, Austria; christian.dejaco{at}gmx.net

https://doi.org/10.1136/annrheumdis-2021-219866

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The letter from Al Nokhatha et al nicely complements our study whose primary purpose was to investigate how COVID-19 related closure of services influenced decisions of rheumatologists and health professionals in rheumatology regarding the management of patients with inflammatory rheumatic and musculoskeletal diseases (RMD).1 2 In contrast to the study by Al Nokhatha et al, we did not include data on vaccinations, which were at that time still far away.

    The authors of this letter correctly point out that vaccination is fundamental to our patients in order to protect them from adverse outcomes of (certain) infections. However, many patients with inflammatory RMD are immunocompromised, and it is well known that in such a clientele, vaccination is challenging regarding both efficacy and …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors All authors drafted the manuscript together and approved its final version.

    • Funding European League against Rheumatism (EULAR), project number EPI025.

    • Competing interests CD received consulting/speaker’s fees from Abbvie, Eli Lilly, Janssen, Novartis, Pfizer, Roche and Sanofi, as well as grant support from Celgene, all unrelated to this manuscript. JWJB received honoraria from Lilly, Roche, Abbvie, Galapagos, SUN all unrelated to this manuscript. FB received consulting/speaker’s fees from Abbvie, Lilly, Horizon Therapeutics, Pfizer and Roche/Chugai, all unrelated to this manuscript.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles